|
Hypercholesterolemia, Familial
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The objective of the present study is to compare the predictive value of an LPA variant, rs10455872, as well as Lp(a) concentration on the prevalence of CVD and on the age of the first CVD event in a cohort of genetically confirmed heterozygous patients with familial hypercholesterolemia (FH).
|
31103339 |
2019 |
|
Hypercholesterolemia, Familial
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The substantial acute reduction of lipoprotein (a) (means: 65%, heterozygous FH; 68%, homozygous FH) has not been reported with other therapies.
|
1414897 |
1992 |
|
Hypercholesterolemia, Familial
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Familial hypercholesterolemia (FH) and elevated lipoprotein(a) [Lp(a)] are inherited disorders associated with premature atherosclerotic cardiovascular disease (ASCVD).
|
30846097 |
2019 |
|
Hypercholesterolemia, Familial
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of the present study was to investigate the associations of lipoprotein (a) [Lp(a)] with the FH phenotype, genotype and roles of Lp(a) in determining CAD risk among patients with and without FH.
|
28351002 |
2017 |
|
Hypercholesterolemia, Familial
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Detection of the Pro664-Leu mutation in the low-density lipoprotein receptor and its relation to lipoprotein(a) levels in patients with familial hypercholesterolemia of Dutch ancestry from The Netherlands and Canada.
|
1493640 |
1992 |
|
Hypercholesterolemia, Familial
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To assess the relationship between LDLR genotype and the plasma levels of PCSK9, LDL-C, and lipoprotein (a) (Lp(a)) in a large cohort of genetically defined FH heterozygotes (HeFH).
|
26371983 |
2015 |
|
Hypercholesterolemia, Familial
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recent literature involving CNVs and dyslipidemias has focused mainly on rare CNVs causing familial hypercholesterolemia, and a common CNV polymorphism as the major determinant of lipoprotein(a) plasma concentrations.
|
29303791 |
2018 |
|
Hypercholesterolemia, Familial
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Phase 2 and 3 clinical trials in patients with moderate and severe hypercholesterolemia (including FH) show that this approach is safe and highly efficacious to lower LDL-C and lipoprotein(a).
|
25248569 |
2014 |
|
Hypercholesterolemia, Familial
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Apolipoprotein(a) polymorphism predicts the increase of Lp(a) by pravastatin in patients with familial hypercholesterolaemia treated with bile acid sequestration.
|
8500516 |
1993 |
|
Hypercholesterolemia, Familial
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The relation of lipoprotein (a) [Lp(a)] and proprotein convertase substilisin/kexin type 9 (PCSK9) levels to coronary artery disease (CAD) has been well established in the general population, while little is known about the association between Lp(a) or PCSK9 and atherosclerotic lesions of different artery sites in patients with familial hypercholesterolemia (FH).
|
30170223 |
2018 |
|
Hypercholesterolemia, Familial
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Until last year, only the LDLR and LPA genes were appreciated as loci within which clinically relevant CNVs contributed to familial hypercholesterolemia and variation in Lp(a) levels, respectively.
|
30664016 |
2019 |
|
Hypercholesterolemia, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
A modified algorithm with lipoprotein(a) added for diagnosis of familial hypercholesterolemia.
|
31436336 |
2019 |
|
Hypercholesterolemia, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lipoprotein(a) [Lp(a)] increases CAD in FH, although the independence of this association relative to other CAD risk factors remains unclear.
|
26340131 |
2015 |
|
Hypercholesterolemia, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study's aim was to determine whether biochemical risk factors such as lipoprotein(a), fibrinogen, homocysteine, and insulin, as well as low-density lipoprotein (LDL) particle size, were predictive of carotid intimamedia thickness (IMT), an early marker of atherosclerosis, in subjects with familial hypercholesterolemia (FH).
|
10235090 |
1999 |
|
Hypercholesterolemia, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
The phenotypic diversity of familial hypercholesterolemia (FH) and lipoprotein(a) hyperlipidemia (Lp(a)-HLP), as defined risks for coronary artery disease with genetic background, and their frequent co-incidence with additional cardiovascular risk factors require a critical revisiting of the current diagnostic and screening criteria as well as therapeutic recommendations established for FH or isolated Lp(a)-HLP, since there is no clear guidance for patient stratification and disease management for combined cases.
|
20129380 |
2009 |
|
Hypercholesterolemia, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genetic traits for familial hypercholesterolemia and high lipoprotein(a) concentrations apparently co-exist and are associated with a higher ASVCD risk than each alone.
|
31393421 |
2019 |
|
Hypercholesterolemia, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, when adjusting LDL cholesterol for lipoprotein(a) cholesterol content the corresponding values were 24 mg/dL for individuals unlikely to have familial hypercholesterolaemia, 22 mg/dL for those with possible familial hypercholesterolaemia, and 21 mg/dL for those with probable or definite familial hypercholesterolaemia (ptrend=0·46).
|
27185354 |
2016 |
|
Hypercholesterolemia, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study confirmed that the MFHS is a strong predictor of prevalent CVD in FH and that the addition of lipoprotein(a) offers a minor improvement in the discrimination of the score.
|
28801029 |
2018 |
|
Hypercholesterolemia, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lipoprotein(a) concentration is associated with plasma arachidonic acid in subjects with familial hypercholesterolaemia.
|
31262370 |
2019 |
|
Hypercholesterolemia, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Elevated lipoprotein(a) and familial hypercholesterolemia in the coronary care unit: Between Scylla and Charybdis.
|
29480541 |
2018 |
|
Hypercholesterolemia, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Determination of apolipoprotein(a) (apo(a)) phenotype and lipoprotein(a) (Lp(a)) concentration in plasma revealed that in many instances, involving individuals with various apo(a) phenotypes, there was no difference in plasma Lp(a) concentration between an FH heterozygote and an unaffected sibling with the same apo(a) phenotype.
|
1830890 |
1991 |
|
Hypercholesterolemia, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Increasing attention has come upon the genetic disorders of familial hypercholesterolemia and elevated lipoprotein(a).
|
28429242 |
2017 |
|
Hypercholesterolemia, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
SLC22A3 is associated with lipoprotein (a) concentration and cardiovascular disease in familial hypercholesterolemia.
|
30772277 |
2019 |
|
Hypercholesterolemia, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study is to investigate the relation between lipoprotein(a) [Lp(a)] and proprotein convertase subtilisin/kexin type 9 (PCSK9) concentrations, and their complex, in patients with potential familial hypercholesterolemia (FH), depending on apo(a) phenotype.
|
30270088 |
2018 |
|
Hypercholesterolemia, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
The metabolic defects in FH extend beyond LDL, and may affect triacylglycerol-rich and high-density lipoproteins, lipoprotein(a) and oxidative stress.
|
25881720 |
2015 |